On June 9, 2025 Axio BioPharma Inc., a next-generation biomanufacturing company using AI to transform mammalian protein production, and Likarda Inc., a leader in advanced drug delivery and formulation technologies, reported a strategic partnership to accelerate innovation in biologic drug development (Press release, Likarda, JUN 9, 2025, View Source [SID1234653786]). This collaboration will integrate Likarda’s proprietary delivery technologies with Axio’s manufacturing capabilities, creating a more efficient and scalable path to clinical manufacturing for clients across the biopharmaceutical sector.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through this collaboration, Axio BioPharma will incorporate Likarda’s proprietary delivery platforms— including its Core-Shell Spherification (CSS) hydrogel technology for encapsulation, stability, and controlled release —into its service offering, enhancing workflows for monoclonal antibodies (mAbs), bispecifics, and Fc-fusions. Likarda will also offer Axio’s discovery-to-GMP manufacturing capabilities to its client base, supporting programs in need of high-quality protein production and scalable manufacturing solutions.

"This partnership brings delivery innovation directly into the development process, helping our clients move faster and make better decisions," said Justin Byers, CEO of Axio BioPharma. "By aligning earlier on both delivery and manufacturing, we reduce friction, shorten timelines, and provide integrated solutions that truly support our clients’ goals."

"At Likarda, we believe that delivery should never be an afterthought—it should be part of the development strategy from day one," said Dr. Stella Vnook, CEO of Likarda Inc. "Partnering with Axio allows us to integrate our encapsulation and formulation technologies earlier in the drug development process, where they can have the greatest impact on stability, efficacy, and patient experience. Importantly, it provides seamless integration to scaled manufacturing for our clients. Together, we’re creating a smarter, more connected path from discovery to clinic."

This collaboration strengthens Axio’s mission of transforming biologic manufacturing through predictive science and digital-first process development. At the same time, it enables Likarda to apply its proprietary delivery technologies earlier in the development cycle, giving clients new efficiencies and expanded therapeutic applications.